Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.

JAMA cardiology - 1 Sept 2022

Cupido Arjen J, Reeskamp Laurens F, Hingorani Aroon D, Finan Chris, Asselbergs Folkert W, Hovingh G Kees, Schmidt Amand F

Abstract excerpt

Importance: Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density lipoprotein cholesterol (LDL-C). Current LDL-C target attainment is low, and novel phase 3 trials are underway to investigate whether CETP inhibitors result in reduction of cardiovascular disease risk in high-risk patients who may be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol Ester Transfer Proteins
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Artery Disease

Share to Diabetes Mellitus, Type 2

Share to Genetic Variation

Share to Macular Degeneration

Share to Mendelian Randomization Analysis

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 35921096
DOI: 10.1001/jamacardio.2022.2333
PMCID: PMC9350849

Genes

CETP
PCSK9
CAD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.PMID 35921096Read ↗

Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.Semantic proximity Read ↗

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular diseaseSemantic proximity Read ↗

Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk.Semantic proximity Read ↗

A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular diseaseSemantic proximity Read ↗

CETP inhibition Reduces Cardiovascular Events by Lowering of Cumulative LDL Exposure: Reconciling Evidence from Human Genetics and Clinical TrialsSemantic proximity Read ↗

Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic strokeSemantic proximity Read ↗

Association of lipids and lipid-lowering drugs with peripheral arterial disease: A Mendelian randomization study.Semantic proximity Read ↗

PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.Semantic proximity Read ↗

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.Semantic proximity Read ↗

CETP and SGLT2 inhibitor combination therapy improves glycemic controlSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.